ALB and diabetic kidney disease: In preclinical studies, researchers constructed Arginine-Glycine-Aspartic acid-Human Serum Albumin-Tacrolimus (RGD-HSA-TAC) nanoparticles to target the delivery of tacrolimus to podocytes, which resulted in a reduction of podocyte injury and albuminuria in mice with diabetic kidney disease (148).